PROCEPT BioRobotics Corporation revised earnings guidance for the year 2023. The Company projects revenue for the full year 2023 to be approximately $131 million, which represents 75% growth over the Company?s prior year revenue. This compares to previous revenue guidance of $128 million.
PROCEPT BioRobotics Corporation
Equities
PRCT
US74276L1052
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.14 USD | +0.19% | -3.88% | +53.04% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.04% | 3.3B | |
-7.57% | 177B | |
-6.99% | 65.54B | |
-4.65% | 47.09B | |
+7.38% | 43.43B | |
+8.14% | 41.77B | |
+14.07% | 29.55B | |
+15.53% | 24.83B | |
-6.53% | 23.97B | |
-5.97% | 23.54B |
- Stock Market
- Equities
- PRCT Stock
- News PROCEPT BioRobotics Corporation
- PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2023